3 Beaten-Down Stocks to Avoid in July 2022

NYSE: DIS | Walt Disney Co. News, Ratings, and Charts

DIS – The Fed has indicated a 75 basis-point interest rate hike in its next meeting, increasing the odds of the economy tipping into a recession in the next 12 months. Given the deteriorating market sentiments, it could be wise to avoid beaten-down stocks The Walt Disney (DIS), Teladoc Health (TDOC), and Affirm Holdings (AFRM) now, which do not have enough fundamental strength to rebound anytime soon. Read on to learn more….

With inflation at a four-decade high, the Fed will likely hike rates 75 basis points this month. This and many more possible interest rate hikes this year have increased the odds of the economy tipping into a recession. 

Moreover, a survey by the University of Michigan showed consumer feelings about the economy plummeted by 14.4% in June, marking a record low for the report. Therefore, the market is expected to remain highly volatile.

Given this backdrop, we think it could be wise to avoid beaten-down stocks The Walt Disney Company (DIS), Teladoc Health, Inc. (TDOC), and Affirm Holdings, Inc. (AFRM), which do not have enough fundamental strength to rebound anytime soon.

The Walt Disney Company (DIS)

DIS operates as an entertainment company worldwide through two segments, Disney Media and Entertainment Distribution; and Disney Parks, Experiences, and Products.

For the fiscal quarter ended April 2, 2022, DIS’ net income from continuing operations decreased 48.5% year-over-year to $470 million. Its EPS for the period declined 48% from the prior-year quarter to $0.26. Moreover, the company missed the consensus EPS estimates in two of the trailing four quarters.

In terms of its forward non-GAAP P/E, DIS is currently trading at 25.03x, 45.7% higher than the industry average of 17.18x. Its forward Price/Sales multiple of 2.15 is 58.5% higher than the industry average of 1.36.

The stock has declined 42.4% over the past year and 33.6% over the past six months to close the last trading session at $99.61.

DIS’ POWR Ratings reflect this bleak outlook. The stock has an overall rating of D, equating to Sell in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

DIS has a Value and Quality grade of D. In the 18-stock F-rated  Entertainment – Media Producers industry; it is ranked #12. Click here to see the additional POWR Ratings for DIS (Growth, Stability, Momentum, and Sentiment).

Teladoc Health, Inc. (TDOC)

TDOC provides virtual healthcare services in the United States and internationally.

For the fiscal quarter ended March 31, 2022, TDOC’s total expenses increased 1,243.9% year-over-year to $7.23 billion. Loss from operations increased 7,776.2% from the prior-year period to $6.67 billion.

The company’s net loss came in at $6.67 billion, up 3,243.1% from the prior-year period, while its net loss per share increased 3,074% to $41.58. Street expects its EPS to remain negative at least this year.

In terms of its forward EV/EBITDA, TDOC is currently trading at 29.86x, 122.4% higher than the industry average of 13.43x. Its forward Price/Cash Flow multiple of 26.18 is 57% higher than the industry average of 16.67.

The stock has slumped 72.8% over the past year and 36.3% over the past three months to close the last trading session at $41.15.

It’s no surprise that TDOC has an overall F rating, which translates to Strong Sell in our POWR Rating system. In addition, TDOC has an F grade in Sentiment and a D in Value, Momentum, Stability, and Quality.

The stock is ranked #81 of 83 stocks in the Medical – Services industry. Click here to see additional TDOC ratings for Growth.

Affirm Holdings, Inc. (AFRM)

AFRM operates a platform for digital and mobile-first commerce in the United States and Canada.

For the fiscal quarter ended March 31, 2022, AFRM’s operating loss increased 8.2% year-over-year to $226.55 million. Total operating expenses increased 32.1% from the prior-year quarter to $581.31 million, while the net loss came in at $54.67 million.

Analysts expect AFRM’s EPS to come in at a negative $0.72 for the quarter ended June 2022 and a negative $0.60 for the quarter ending September 2022. AFRM missed the consensus EPS estimates in three of the trailing four quarters.

In terms of its forward EV/Sales, AFRM is currently trading at 6.98x, 153.2% higher than the industry average of 2.76x. Its forward Price/Sales multiple of 5.57 is 98.3% higher than the industry average of 2.81.

AFRM’s shares have declined 83.2% over the past nine months to close the last trading session at $26.03.

AFRM’s poor prospects are reflected in its POWR Ratings. The stock has an overall F rating, equating to a Strong Sell in our proprietary rating system.

AFRM also has a Stability grade of F and a Value, Quality, and Sentiment grade of D. It is ranked #79 out of the 80 stocks in the Technology – Services industry. Click here to see the additional POWR Ratings for Growth and Momentum for AFRM.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


DIS shares were trading at $102.77 per share on Wednesday afternoon, up $3.16 (+3.17%). Year-to-date, DIS has declined -33.65%, versus a -16.61% rise in the benchmark S&P 500 index during the same period.


About the Author: Komal Bhattar


Komal's passion for the stock market and financial analysis led her to pursue investment research as a career. Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
DISGet RatingGet RatingGet Rating
TDOCGet RatingGet RatingGet Rating
AFRMGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Expert Predicts 3-6 Months of Pain

2 important market developments are leading market expert Steve Reitmeister to predict 3 to 6 months of painful market conditions pushing the S&P 500 (SPY) lower. Read on for the full story...

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more...

3 Tech Stocks Analysts Say Are "Strong Buys" for 2025

The technology industry is well-positioned for significant growth thanks to the rapid advancements in emerging technologies and the digitization of business operations. Amid this backdrop, fundamentally solid tech stocks Adobe (ADBE), Leidos Holdings (LDOS), and DocuSign (DOCU) could be strong buys for 2025. Continue reading...

3 Tech Stocks Under $20 With Breakout Potential

The tech sector is the core of innovation, from transforming industries to powering economic progress. Amid this backdrop, investors could consider buying sound under $20 tech stocks Vimeo (VMEO), PubMatic (PUBM), and Eventbrite (EB). Keep reading…

How Bad Will 2025 Be for Stocks?

As January goes...so goes the stock market. And right now that saying bodes poorly for the year ahead. Especially for the S&P 500 (SPY). That is why Steve Reitmeister shares 2 different paths the market could take in 2025 and how to get your portfolio on the right side of the action.

Read More Stories

More Walt Disney Co. (DIS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All DIS News